A critical need exists for a robust supply of clinician scientists trained in clinical pharmacology, a discipline ideally suited to our nation's current efforts to augment the translation of new and effective therapies into clinical practice. This application seeks to continue an established program that has a track record of excellence in training successful translational clinician scientists. The program has grown in depth and quality over the last funding period. The addition of new faculty has made possible an increase in the depth of programming and has continued a strong emphasis on minority recruitment. The established program excellence in drug disposition and pharmacogenomics has been augmented with deeper didactic training in drug development. A core faculty of 13, selected on the basis of quality research related to clinical pharmacology, peer-reviewed funding and training success and 32 supporting faculty now allow this program to serve as a central pillar within the institution's clinical research enterprise. The program contributes to a wide range of peer-reviewed research and is the key to NIH K-30 Clinical Investigator training program. The core faculty has funded research programs in cancer, cardiovascular, gastrointestinal, pediatric, obstetric and geriatric clinical pharmacology, as well as drug-induced liver disease, drug metabolism and disposition, drug interactions, pharmacogenetics and pharmacogenomics, ethics in therapeutic research and therapeutic outcomes. Trainees attend weekly journal clubs, clinical pharmacology seminars, clinical case conferences, and an organized weekly didactic program that runs year round in a two year cycle. In depth didactic training now concentrates on pharmacokinetics, pharmacogenomics, drug development, individualized therapeutics, and clinical trial design. Trainees may also elect to participate in the Indiana University Master of Science in Clinical Investigation. The core faculty selects trainees for the 2 to 3 year program based on their potential as clinician scientists from candidates with M.D. or M.D./ Ph.D. degrees and sufficient clinical training for primary specialty certification Exceptional candidates with Ph.D. or Pharm.D. degree's in areas related to the objectives of the program have be selected. Since first funded in 1992, qualified applicants have filled the training grant slots, and additional trainees have been funded from other sources. The program has generated stably funded academic physician scientists and leaders in the pharmaceutical industry and continues to serve a national role in training clinical pharmacologists.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1-BRT-5 (PG))
Program Officer
Okita, Richard T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Indiana University-Purdue University at Indianapolis
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Kidwell, Kelley M; Harte, Steven E; Hayes, Daniel F et al. (2014) Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer 120:2403-11
Pierson, Rebecca C; Gordon, Sashana S; Haas, David M (2014) A retrospective comparison of antibiotic regimens for preterm premature rupture of membranes. Obstet Gynecol 124:515-9
Metzger, Ingrid F; Quigg, Troy C; Epstein, Noam et al. (2014) Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers. Curr Ther Res Clin Exp 76:64-9
Schelleman, H; Han, X; Brensinger, C M et al. (2014) Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol 78:639-48
Quinney, Sara K; Malireddy, Srikar R; Vuppalanchi, Raj et al. (2013) Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. Eur J Clin Pharmacol 69:439-48
Henry, N Lynn; Skaar, Todd C; Dantzer, Jessica et al. (2013) Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. Breast Cancer Res Treat 138:807-16
Kreutz, Rolf P; Owens, Janelle; Breall, Jeffrey A et al. (2013) C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting. Blood Coagul Fibrinolysis 24:321-6
Thacker, David L; Modak, Anil; Flockhart, David A et al. (2013) Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity? J Breath Res 7:016001
Lu, Deshun; Owens, Janelle; Kreutz, Rolf P (2013) Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes. Thromb Res 132:e94-8
Benson, Eric A; Skaar, Todd C (2013) Incubation of whole blood at room temperature does not alter the plasma concentrations of microRNA-16 and -223. Drug Metab Dispos 41:1778-81

Showing the most recent 10 out of 71 publications